Table 3 Antineoplastic drugs significantly associated with vitiligo (meeting Criteria of all four disproportionality analysis methods).
From: Real world pharmacovigilance study of antineoplastic drug related vitiligo risks
DRUG | ATC code | Case Numbers | ROR(95%Cl) | PRR(χ2) | EBGM(EBGM05) | IC(IC025) |
|---|---|---|---|---|---|---|
Mogamulizumab | L01FX09 | 11 | 85.15(47.03–154.16) | 84.92(906.46) | 84.38(51.35) | 6.4(4.73) |
Ipilimumab | L01FX04 | 67 | 46.32(36.28–59.14) | 46.25(2851.99) | 44.51(36.28) | 5.48(3.81) |
Talimogene Laherparepvec | L01XL02 | 4 | 45.03(16.87–120.19) | 44.96(171.55) | 44.86(19.73) | 5.49(3.82) |
Pembrolizumab | L01FF02 | 126 | 29.97(25–35.93) | 29.94(3269.28) | 27.84(23.92) | 4.8(3.13) |
Nivolumab | L01FF01 | 147 | 28.52(24.08–33.77) | 28.5(3570.1) | 26.17(22.72) | 4.71(3.04) |
Atezolizumab | L01FF05 | 30 | 17.56(12.24–25.2) | 17.55(460.19) | 17.27(12.76) | 4.11(2.44) |
Ribociclib | L01EF02 | 37 | 14.09(10.17–19.52) | 14.09(440.28) | 13.81(10.51) | 3.79(2.12) |
Encorafenib | L01EC03 | 4 | 8.8(3.3–23.47) | 8.8(27.58) | 8.78(3.86) | 3.13(1.47) |
Temozolomide | L01AX03 | 10 | 8.46(4.54–15.75) | 8.46(65.39) | 8.42(5) | 3.07(1.41) |
Dabrafenib | L01EC02 | 8 | 7.7(3.85–15.43) | 7.7(46.44) | 7.67(4.29) | 2.94(1.27) |
Busulfan | L01AB01 | 5 | 7.57(3.14–18.2) | 7.56(28.4) | 7.54(3.62) | 2.92(1.25) |
Pemetrexed | L01BA04 | 9 | 7.37(3.83–14.19) | 7.37(49.28) | 7.34(4.24) | 2.87(1.21) |
Trametinib | L01EE01 | 5 | 5.78(2.4–13.9) | 5.78(19.7) | 5.76(2.77) | 2.53(0.86) |
Abemaciclib | L01EF03 | 4 | 4.69(1.76–12.51) | 4.69(11.58) | 4.68(2.06) | 2.23(0.56) |
